Another Sea Change In Myeloma Promised By New Therapies, Combos
Darzalex made a splash with impressive Phase III data in relapsed multiple myeloma at the EHA and ASCO meetings, but a range of other drugs are on the way, including a next-generation CD38 inhibitor from Sanofi, checkpoint inhibitors and Roche's BCL-2 Venclexta.
You may also be interested in...
ALCYONE Paves Way For J&J/Genmab's Darzalex In Frontline Myeloma
Data supporting a role for J&J/Genmab's anti-CD38 monoclonal antibody in newly diagnosed multiple myeloma are "as good as could be expected," but the backbone regimen in the trial is rarely used in the US.
More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals
Sponsors of established products like Amgen's Kyprolis and Blincyto and Bristol's Sprycel work to bulk up labeling with new indications while FDA reviews at least six novel agents for blood cancers.
Oncology Combo Drugs Face UK Market Access Disappointment
New oncology drugs forming new treatment combinations will face a tough ride through England’s influential health technology appraisal body, NICE.